Chimerix Valuation

Is CXF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CXF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CXF (€1.02) is trading below our estimate of fair value (€221.81)

Significantly Below Fair Value: CXF is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CXF?

Other financial metrics that can be useful for relative valuation.

CXF key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does CXF's PB Ratio compare to its peers?

The above table shows the PB ratio for CXF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.6x
HPHA Heidelberg Pharma
3.1x-33.0%€112.3m
2INV 2invest
1xn/a€59.8m
MDG1 Medigene
1.1x-4.1%€22.0m
CNW co.don
1xn/a€6.5m
CXF Chimerix
0.7x31.4%€83.8m

Price-To-Book vs Peers: CXF is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (1.7x).


Price to Earnings Ratio vs Industry

How does CXF's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.5%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.5%
n/an/an/a
No more companies

Price-To-Book vs Industry: CXF is good value based on its Price-To-Book Ratio (0.7x) compared to the European Biotechs industry average (2.5x).


Price to Book Ratio vs Fair Ratio

What is CXF's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CXF PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CXF's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CXF forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.85
€6.53
+672.0%
32.6%€10.26€4.67n/a5
Nov ’25€0.83
€6.46
+680.1%
32.6%€10.15€4.61n/a5
Oct ’25€0.78
€6.16
+690.3%
30.9%€9.92€4.51n/a6
Sep ’25€0.83
€6.16
+644.5%
30.9%€9.92€4.51n/a6
Aug ’25€0.77
€6.48
+743.8%
29.7%€10.18€4.63n/a6
Jul ’25€0.80
€6.48
+712.1%
29.7%€10.18€4.63n/a6
Jun ’25€0.88
€6.55
+647.4%
27.5%€10.29€4.68n/a7
May ’25€0.86
€6.55
+664.0%
27.5%€10.29€4.68n/a7
Apr ’25€0.95
€6.46
+583.1%
27.5%€10.15€4.61n/a7
Mar ’25€1.06
€6.46
+506.8%
27.5%€10.15€4.61n/a7
Feb ’25€0.84
€6.91
+725.0%
25.7%€10.36€4.71n/a6
Jan ’25€0.81
€6.91
+749.1%
25.7%€10.36€4.71n/a6
Dec ’24€0.91
€6.91
+658.0%
25.7%€10.36€4.71n/a6
Nov ’24€0.89
€6.74
+661.1%
25.7%€10.12€4.60€0.836
Oct ’24€0.89
€6.74
+655.9%
25.7%€10.12€4.60€0.786
Sep ’24€0.97
€6.74
+595.7%
25.7%€10.12€4.60€0.836
Aug ’24€1.05
€7.02
+569.0%
27.8%€10.08€4.58€0.776
Jul ’24€1.10
€7.02
+538.0%
27.8%€10.08€4.58€0.806
Jun ’24€1.26
€7.09
+461.5%
27.8%€10.17€4.62€0.886
May ’24€1.05
€7.24
+592.6%
29.7%€10.21€4.64€0.865
Apr ’24€1.14
€7.24
+538.0%
29.7%€10.21€4.64€0.955
Mar ’24€1.47
€7.98
+442.5%
26.2%€10.97€5.99€1.065
Feb ’24€1.62
€7.98
+393.1%
26.2%€10.97€5.99€0.845
Jan ’24€1.72
€7.98
+364.0%
26.2%€10.97€5.99€0.815
Dec ’23€2.22
€7.98
+259.2%
26.2%€10.97€5.99€0.915
Nov ’23€1.87
€7.99
+327.1%
26.2%€10.99€6.00€0.895

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies